PHILADELPHIA –Stand Up To Cancer (SU2C) is making $7.5 million in research grants available to early-career scientists who are pursuing innovative cancer research projects focusing on immuno-oncology, the American Association for Cancer Research (AACR) announced today. Funded by a grant from SU2C Visionary Supporter, Bristol-Myers Squibb Company, a total of 10 Innovative Research Grants (IRGs) will be available, each up to $750,000, over three years.
"Immuno-oncology is an exciting field in research today," said William G. Kaelin Jr., MD, professor of medicine and associate director of basic science at the Dana-Farber Cancer Institute and Harvard Medical School and chair of the SU2C Innovative Research Grant Committee. "It has yielded a number of revolutionary new approaches to cancer treatment, and we are eager to find and support scientists early in their careers who can help move the field even further forward."
The IRG program is open to young investigators no more than seven years into their first independent, tenure-track (or equivalent) appointment, pursuing novel, high-risk, high-reward cancer immunology research proposals that have significant potential for translation to clinical application and hold great promise for advancing SU2C's overarching goal of improving and saving lives. Provided that these criteria are met, proposals may focus on any discipline within basic, translational, or clinical research.
"There is potential for immuno-oncology in a wide range of cancers, and so investment in new research is critical," said Julie Hambleton, MD, vice president, head, U.S. Medical, Bristol-Myers Squibb. "As part of our ongoing support of Stand Up To Cancer, we are proud to help the next generation of researchers progress the field forward with new and exciting research that has the potential to lead to advancements for the benefit of patients."
The deadline for proposals from eligible investigators is at 12:00 p.m. ET on January 12, 2017. See the program guidelines. Submit proposals online via proposalCENTRAL.
The SU2C Innovative Research Grant Committee, composed of leading cancer physician-scientists and researchers, will review proposals and select finalists who will be invited to present their proposals to the committee in person in early 2017.
Review general information on eligibility criteria, the application process, and the research conducted by previous IRG recipients. Inquiries may also be directed to AACR's Scientific Review and Grants Administration Department at 215-446-7190.
As Scientific Partner of SU2C since its launch in 2008, the AACR provides scientific leadership, expert peer review, and grants administration for SU2C's extensive research program.